10 - 12 July 2021
EAACI Hybrid Congress 2021

Industry Section

All Hybrid Industry Symposia



Saturday, 10 July 2021


Company Sponsored Symposia (CSS) /  Satellite Symposia (SAT) /  Company Sponsored Mini Symposia (CSMS)

All Hybrid Symposia are located at ICE Krakow in Hall S2 and are also available on the EAACI Hybrid Congress 2021 digital platform. 


CSMS 1-1

09:00 - 09:30

AstraZeneca: Relegating OCS to last resort: Creating a paradigm shift in asthma management

                                   

OCS use in asthma – what is the problem, and why does it matter?

Speaker: Jorge Maspero, Argentina        

Identifying severe and uncontrolled asthma – tools for improving clinical care            

Speaker: Steve Holmes, UK         

Panel discussion: Driving OCS stewardship in clinical practice

Speakers: Jorge Maspero, Argentina; Steve Holmes, UK





CSS 1-1

10:00 - 11:30

ALK: Best in both worlds - Demonstrating long-term effectiveness of allergy immunotherapy in the real world 

Chair: Natalija Novak, Germany

                               

REWEAL: REal World Evidence in Allergy

Speaker: Natalija Novak, Germany

Randomised controlled trials: The start of our evidence-based journey

Speaker: Stephen R. Durham, UK             

Real world evidence: New horizons, and reasons to believe

Speaker: Nick Freemantle, UK   

The big REWEAL: Real patients. Real questions. Answered!

Speaker: Benedikt Fritzsching, Germany

Panel discussion

Speaker: All


 

CSS 1-2

12:00 - 13:30

AMGEN and AstraZeneca: TSLP: a key epithelial cytokine at the top of the asthma inflammatory cascade

Chairs: Andrew Menzies-Gow, UK & Stephanie Korn, Germany

               

Raising the bar for the management of severe asthma: remission as the goal of therapy              

Speaker: Andrew Menzies-Gow, UK        

The airway epithelium as first line of defence: diverse downstream inflammatory cascades in response to viruses and allergens

Speaker: Celeste Porsbjerg, Denmark

Triggers of exacerbations: what is driving severe asthma?

Speaker: Stephanie Korn, Germany

How might epithelial cytokines be driving asthma in our patients?

Speaker: Ioana Agache, Romania              

Audience Q&A, discussion and concluding remarks

Andrew Menzies-Gow, UK; Stephanie Kom, Germany; Ioana Agache, Romania




CSS 1-3

14:00 - 15:30

Thermo Fisher Scientific: Asthma, does allergy matter?

Chair: Pablo Rodríguez del Río, Spain



Welcome and introduction

Speaker: Pablo Rodríguez del Río, Spain

Every doctor should phenotype asthmatic patients

Speaker: Thomas Casale, USA

How to improve management and care for the wheezing child

Speaker: Andrew Liu, USA

Updates in allergen component testing and what’s in the pipeline

Speaker: Magnus Borres, Sweden

Q&A

Speakers:  Pablo Rodríguez del Río, Spain; Thomas Casale, USA; Andrew Liu, USA; Magnus Borres, Sweden

 

 

CSS 1-4

16:00 - 17:30

Sanofi Genzyme and Regeneron: Navigating Type 2 Inflammation across the skin, airway, and esophagus

Chair: William Busse, USA

Connecting Type 2 Inflammation to clinical characteristics of disease

Speaker: Oscar Palomares, Spain

Breaking barriers: How relevant are biomarkers of Type 2 Inflammation?

Speaker: William Busse, USA

Clinical implications: Why target Type 2 Inflammation?

Speakers: Natalija Novak, Germany & William Busse, USA

Question and answer session

Speakers: All Faculty



SAT 1-1

18:00 - 19:00

GSK: Targeted therapy for patients with severe eosinophilic asthma – an interactive conversation with experts

Chairs: Peter Howarth, UK; Maciej Kupczyk, Poland

                               

Welcome address from chairs

Speakers: Peter Howarth, UK; Maciej Kupczyk, Poland    

Elevating care for severe eosinophilic asthma patients through precision medicine        

Speaker: Santiago Quirce, Spain

Addressing your clinical questions in the treatment of severe eosinophilic asthma: Audience-led discussion

Speakers: Peter Howarth, UK; Maciej Kupczyk, Poland

Closing remarks and Q&A

Speakers: Peter Howarth, UK; Maciej Kupczyk, Poland





Sunday, 11 July 2021




CSMS 2-1

09:00 - 09:30

Allergy Therapeutics: Ameliorating atopy by targeted micronutrient supplementation with beta-lactoglobulin

                                                               

Ameliorating atopy by targeted micronutrient supplementation with beta-lactoglobulin

Speaker: Franziska Roth-Walter, Austria





CSS 2-1

10:00 - 11:30

Stallergenes Greer: Supporting individual patients’ needs: AIT still an unmatched model of personalized medicine for allergy

Chairs: Giorgio Walter Canonica, Italy; Ruby Pawankar, Japan; Marek Jutel, Poland

               

AIT still a unique model of personalized medicine

Speaker: Giorgio Walter Canonica, Italy

Maximizing patient’s chances of better outcomes

Speaker: Oliver Pfaar, Germany

Harnessing each patient’s clinical profile in real life to adapt AIT

Speaker: Davide Caimmi, France

Making the digital shift in respiratory allergies

Speaker: Jean Bousquet, Germany





CSS 2-2

12:00 - 13:30

DBV Technologies: Patients with peanut allergy: the hope for a better life?       

Chairs: Antonella Muraro, Italy;  Philippe Eigenmann, Switzerland             

               

Introduction

Speaker: Antonella Muraro, Italy

The daily burden of peanut allergy

Speaker: Katharina Blümchen, Germany

Early management of peanut allergy: the window of opportunity?

Speaker: Jonathan Hourihane, Ireland    

Managing patients with peanut allergy today and tomorrow

Speaker: Helen Brough, UK         

Conclusion

Speaker: Philippe Eigenmann, Switzerland




SAT 2-1

14:00 - 15:00

Sanofi Genzyme and Regeneron: Yesterday’s vision is today’s opportunity to address Type 2 Inflammation in pediatric and adult atopic dermatitis patients          

Introduction

Speaker: Tilo Biedermann, Germany

Common underlying pathophysiology of Type 2 Inflammatory diseases and implications for atopic dermatitis  

Speaker: Tilo Biedermann, Germany      

Evolving treatments for Type 2 Inflammation in atopic dermatitis across age groups

Speaker: Lisa Beck, USA

Live Q&A

Speakers: Tilo Biedermann, Germany; Lisa Beck, USA





CSMS 2-2

15:15 - 15:45

Allergopharma: Allergen composition of preparations translate into clinical outcomes of AIT

Chair: Susanne Lau, Germany  
                                  

Relevance of molecular evolution in allergic patients

Speaker: Marek Jutel, Poland     

Characterizing the allergen symphony of AIT products

Speaker: Petra Zieglmayer, Austria





CSS 2-3

16:00 - 17:30

LETI Pharma: The complex world of allergy. Patient’s needs in real life

Chair: Luis Delgado, Portugal

Allergic patients: The complexity of personalized medicine

Speaker: Jeronimo Carnés, Spain

The future is now: Biomarkers

Speaker: Mohamed Shamji, U.K

RWE: What is happening with our patients?

Speaker: Ralph Mösges, Germany





IWS 2-1

Hall S3A (100 pax) / Channel 3 – EAACI Lab1

17:15 - 18:45

HAL Allergy: Meet the experts on AIT in Food Allergy

Welcome & Introduction

Current Developments of AIT in Food Allergies

Speaker: Ronald van Ree, The Netherlands

Who are the right candidates for AIT in food allergy?

Speaker: Montserrat Fernandez Rivas, Spain

Q & A Podium Discussion

Speakers: Ronald van Ree, The Netherlands; Montserrat Fernandez Rivas, Spain









SAT 2-2

18:00 - 19:00

Sanofi Genzyme and Regeneron: Managing severe asthma and CRSwNP: Through the lens of Type 2 Inflammation        

Chairs: Santiago Quirce, Spain; Ekkehard Beck, Germany; Enrico Heffler, Italy; Wytske J. Fokkens, The Netherlands

Opening Remarks

Speakers: Santiago Quirce, Spain; Ekkehard Beck, Germany; Enrico Heffler, Italy

Wytske J. Fokkens, The Netherlands

Type 2 Inflammation: The common underlying pathway

Speaker: Enrico Heffler, Italy      

Panel discussion: What have we learned about Type 2 Inflammation from clinical experience?

Speakers: Santiago Quirce, Spain; Ekkehard Beck, Germany; Enrico Heffler, Italy; Wytske J. Fokkens, The Netherlands

Dupilumab: Targeting Type 2 Inflammation to effectively treat  asthma and CRSwNP

Speakers: Ekkehard Beck, Germany; Wytske J. Fokkens, The Netherlands

Audience Q&A - Closing remarks

Speakers: Santiago Quirce, Spain; Ekkehard Beck, Germany; Enrico Heffler, Italy; Wytske J. Fokkens, The Netherlands






Monday, 12 July 2021

 

SAT 3-1

10:15 - 11:15

Nestlé Health Science: Advancing the management of CMPA with HMO: Priming the immune system

Chair: Liam O'Mahony, Ireland

 

Introduction

Speaker: Liam O'Mahony, Ireland

The clinical relevance of HMO in infants with CMPA

Speaker: Yvan Vandenplas, Belgium

HMO shaping the gut microbiome in infants with CMPA

Speaker: Ralf Heine, Switzerland

Immunological and microbial effects of HMO in experimental models of food allergy

Speaker: Sophie Nutten, Switzerland





CSS 3-1

12:00 - 13:30

AstraZeneca: Advances in eosinophilic diseases             

Chair: David Jackson, UK

                                               

Introduction to the role of esinophils in health and their role in airway inflammation 

Speaker: David Jackson, UK         

The central role of eosinophils in eosinophilic oesophagitis       

Speaker: Arjan Bredenoord, Netherlands             

The emerging role of esinophils in chronic urticaria        

Speaker: Sabine Altrichter, Austria           

Q&A session and meeting close

Speakers: David Jackson, UK; Arjan Bredenoord, Netherlands; Sabine Altrichter, Austria





Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel